MedTrace Logo

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

NCT02791035 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-07-05

No results posted yet for this study

Summary

The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

Oral administration of Ipragliflozin

Sponsors & Collaborators

  • Severance Hospital

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Kyung Hee University Hospital at Gangdong

    collaborator OTHER

  • Astellas Pharma Korea, Inc.

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02791035 on ClinicalTrials.gov